Safety and tolerability of overdosed artificial tears by abraded rabbit corneas

Daull P., Raymond E., Feraille L., Garrigue J.-S.

2018
Journal of Ocular Pharmacology and Therapeutics

View publication

Therapeutic Area

Front of the eye (FOTE)
Technology

Drug Delivery
Categories

Preclinical development

Affiliations

SANTEN SAS, Novagali Innovation Center, 1, rue Pierre Fontaine, Evry Cedex, F-91458, France; Iris Pharma, La Gaude, France

Related Publications

Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases

Daull P., Baudouin C., Liang H., Feraille L., Barabino S., Garrigue J.-S.

Ocular surface response of two preservative-free cylcosporine A emulsion eye drops in a mouse model of dry eye

Daull P., Nagano T., Gros E., Feraille L., Barabino S., Garrigue J.-S.

Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.

View all Front of the eye (FOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022